Equities analysts forecast that Mersana Therapeutics Inc (NASDAQ:MRSN) will report ($0.37) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Three analysts have issued estimates for Mersana Therapeutics’ earnings, with estimates ranging from ($0.39) to ($0.35). Mersana Therapeutics posted earnings per share of ($0.75) during the same quarter last year, which would indicate a positive year over year growth rate of 50.7%. The firm is expected to issue its next earnings results on Tuesday, November 12th.
According to Zacks, analysts expect that Mersana Therapeutics will report full year earnings of ($0.61) per share for the current financial year, with EPS estimates ranging from ($0.78) to ($0.38). For the next fiscal year, analysts anticipate that the business will post earnings of ($1.41) per share, with EPS estimates ranging from ($1.84) to ($1.20). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research firms that cover Mersana Therapeutics.
Mersana Therapeutics (NASDAQ:MRSN) last posted its earnings results on Thursday, August 8th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.38) by $0.02. Mersana Therapeutics had a negative net margin of 77.78% and a negative return on equity of 63.92%. The business had revenue of $0.20 million for the quarter, compared to analysts’ expectations of $1.08 million.
Several large investors have recently modified their holdings of MRSN. Bank of New York Mellon Corp grew its holdings in shares of Mersana Therapeutics by 19.2% in the fourth quarter. Bank of New York Mellon Corp now owns 39,203 shares of the company’s stock worth $160,000 after purchasing an additional 6,306 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of Mersana Therapeutics by 4.7% in the fourth quarter. Geode Capital Management LLC now owns 128,232 shares of the company’s stock worth $523,000 after purchasing an additional 5,798 shares during the last quarter. Two Sigma Investments LP purchased a new stake in Mersana Therapeutics in the fourth quarter worth about $277,000. Bank of America Corp DE lifted its stake in Mersana Therapeutics by 1,409.6% in the fourth quarter. Bank of America Corp DE now owns 31,807 shares of the company’s stock worth $129,000 after acquiring an additional 29,700 shares during the period. Finally, Hikari Power Ltd lifted its stake in Mersana Therapeutics by 5.7% in the first quarter. Hikari Power Ltd now owns 90,246 shares of the company’s stock worth $475,000 after acquiring an additional 4,850 shares during the period. 77.40% of the stock is currently owned by hedge funds and other institutional investors.
NASDAQ MRSN traded down $0.08 on Friday, hitting $2.69. The stock had a trading volume of 3,912 shares, compared to its average volume of 145,537. Mersana Therapeutics has a 52-week low of $2.77 and a 52-week high of $15.93. The company has a quick ratio of 6.24, a current ratio of 6.24 and a debt-to-equity ratio of 0.02. The company has a market capitalization of $134.82 million, a P/E ratio of -0.99 and a beta of 1.37. The business has a 50-day moving average of $3.75.
Mersana Therapeutics Company Profile
Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company focusing on the development of antibody drug conjugate (ADC) for cancer patients with unmet need. The company develops Dolaflexin, a platform, which is used to generate a pipeline of proprietary ADC product candidates to address patient populations that are not amenable to treat with traditional ADC-based therapies.
Recommended Story: Why do earnings reports matter?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Mersana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mersana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.